Apollo Endosurgery, Inc. to Report Second Quarter Results on July 23, 2019

AUSTIN, Texas–(BUSINESS WIRE)–Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the first quarter ended June 30, 2019 on Tuesday, July 23, 2019, after the U.S. stock markets close.

Apollo will hold a conference call on Tuesday, July 23, 2019 at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. The dial-in numbers are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers. The conference ID number is 3369396. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at www.apolloendo.com.

A replay of the webcast will be made available on Apollo’s website, www.apolloendo.com, shortly after completion of the call.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Apollo’s common stock is traded on Nasdaq Global Market under the symbol “APEN”. For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

Contacts

Apollo Endosurgery, Inc.

John Gillings, 512-279-5100

Investor Relations

investor-relations@apolloendo.com

Staff

Recent Posts

RPI Consultants Presents Annual Scholarship to Healthcare Technology Professional

BALTIMORE, Feb. 5, 2026 /PRNewswire/ -- RPI Consultants, a leading ERP implementation, optimization, and software firm…

2 hours ago

BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration

LONDON, Feb. 5, 2026 /PRNewswire/ -- BioPhorum, the pharmaceutical industry's most trusted collaborative network for…

2 hours ago

BC Platforms partners with OmicsBank to expand access to large-scale real-world and multi-omics data from India and the UAE

Patient catchment now includes 187 million+ patient lives, enables advanced analytics and AI modeling for…

2 hours ago

Electron Microscopy Market to Reach $10.3 billion, Globally, by 2034 at 8.1% CAGR: Allied Market Research

The electron microscopy market is driven by rapid advancements in nanotechnology, increase in demand for…

2 hours ago

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / BioNxt Solutions Inc. ("BioNxt" or…

2 hours ago

Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism

In the study, [68Ga]Ga-Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity…

5 hours ago